Table 2.
Baseline characteristics of BMF analysis and all-treated populations at entry into TED12037
| Characteristic | BMF analysis population (n = 21) | All-treated population (n = 43) |
|---|---|---|
| Mean age, years (SD) | 63.5 (10.7) | 63.8 (10) |
| Sex, n (%) | ||
| Male | 12 (57) | 26 (60) |
| Female | 9 (43) | 17 (40) |
| Disease subtype, n (%) | ||
| PMF | 12 (57) | 30 (70) |
| Post-ET MF | 1 (5) | 2 (5) |
| Post-PV MF | 8 (38) | 11 (26) |
| Risk status [27], n (%) | ||
| High | 8 (38) | 15 (35) |
| Intermediate | 13 (62) | 28 (65) |
| JAK2V617F mutation status, n (%) | ||
| Positive | 19 (90) | 39 (91) |
| Negative | 2 (10) | 4 (9) |
| Last fedratinib dose in TED12037, mg/day | ||
| 120 | 3 (14) | 3 (7) |
| 240 | 2 (10) | 4 (9) |
| 360 | 1 (5) | 5 (12) |
| 400 | 0 | 1 (2) |
| 440 | 2 (10) | 4 (9) |
| 520 | 7 (33) | 11 (26) |
| 600 | 1 (5) | 3 (7) |
| 680 | 5 (24) | 12 (28) |
| BMF grade, n (%) | ||
| 0 | 0 (0) | 0 (0) |
| 1 | 2 (10) | 2 (5) |
| 2 | 10 (48) | 10 (23) |
| 3 | 9 (43) | 10 (23)a,b |
| Spleen size (cm), median (range) | 18 (4–34) | 18 (4–34) |
| Haemoglobin (g/dL), median (range) | 9.7 (7.4–15.2) | 9.3 (7.3–15.2) |
| White blood cells (×109/L), median (range) | 16.4 (2.1–103.3) | 14.9 (2.1–103.3) |
Percentages may not sum to 100 due to rounding
aOne patient had a baseline BMF reading but no subsequent BMF readings and was therefore excluded from the BMF population
bTwenty-one patients had missing baseline BMF data